Oncology Institute (NASDAQ: TOI) chief files Form 4 with no trades

Rhea-AI Filing Summary

Oncology Institute, Inc. insider Jeffrey Langsam, the company’s Chief Clinical Officer, filed a Form 4 reporting his status as an officer but no transactions in company securities. The provided data show no purchases, sales, exercises, gifts, or other changes in his reported holdings.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Derivative exercises: 0 transactions +2 more

5 metrics

Buy transactions 0 transactions Form 4 transactionSummary buyCount

Sell transactions 0 transactions Form 4 transactionSummary sellCount

Derivative exercises 0 transactions Form 4 transactionSummary exerciseCount

Gift transactions 0 transactions Form 4 transactionSummary giftCount

Tax-withholding dispositions 0 transactions Form 4 transactionSummary taxWithholdingCount

Key Terms

Form 4, reporting person, derivative transactions

3 terms

Form 4 regulatory

"filed a Form 4 reporting his status as an officer"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

reporting person regulatory

"lists Chief Clinical Officer Jeffrey Langsam as the reporting person"

derivative transactions financial

"no derivative transactions for Jeffrey Langsam"

Derivative transactions are contracts whose value depends on the price or performance of something else—like stocks, bonds, currencies, interest rates or commodities. Think of them as insurance or bets about a future price: investors use them to protect against losses, lock in prices, or try to amplify returns, but they can also magnify losses, create cash demands and expose a firm to the risk that the other party won’t meet its obligation, so they can materially affect a company’s financial stability and volatility.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Langsam Jeffrey

(Last) (First) (Middle)

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Clinical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Pursuant to a Unanimous Written Consent of the Board of Directors of the Issuer dated April 21, 2026, the reporting person was determined to no longer be an officer of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Jeffrey Langsam	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What does the latest Form 4 for TOI’s Jeffrey Langsam show?

The Form 4 for Oncology Institute, Inc. (TOI) lists Chief Clinical Officer Jeffrey Langsam as the reporting person. The provided summary shows no reported purchases, sales, exercises, or other changes in his beneficial ownership during the covered period.

Did TOI’s Chief Clinical Officer buy or sell shares in this Form 4?

No transactions are shown for Chief Clinical Officer Jeffrey Langsam in this Form 4. The transaction summary reports zero buys, zero sells, zero exercises, and no other types of changes in his reported position for the period covered.

Are there any derivative security exercises in this TOI Form 4 filing?

The filing summary indicates no derivative transactions for Jeffrey Langsam. ExerciseCount and derivativeTransactionCount are both zero, meaning there were no reported stock option exercises, conversions, or other derivative-related activities in this Form 4 data.

Does this TOI Form 4 indicate any gifts or tax-withholding share transfers?

According to the transaction summary, there are no gifts or tax-withholding dispositions reported. GiftCount and taxWithholdingCount are zero, so the filing does not reflect any transfers classified as gifts or shares withheld for taxes.

What does a Form 4 with zero transactions mean for TOI investors?

A Form 4 with zero reported transactions simply records that no changes in the insider’s reported holdings occurred during the period. It is largely administrative and does not alter the investment thesis on Oncology Institute, Inc. by itself.